DelveInsight’s “Bruton’s Tyrosine Kinase Hematological Cancer Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Bruton’s Tyrosine Kinase Hematological Cancer, historical and forecasted epidemiology as well as the Bruton’s Tyrosine Kinase Hematological Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Bruton’s Tyrosine Kinase Hematological Cancer market report provides current treatment practices, emerging drugs, Bruton’s Tyrosine Kinase Hematological Cancer market share of the individual therapies, current and forecasted Bruton’s Tyrosine Kinase Hematological Cancer market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Bruton’s Tyrosine Kinase Hematological Cancer treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Bruton’s Tyrosine Kinase Overview
Bruton’s Tyrosine Kinase is a soluble tyrosine kinase with central roles in the development, maturation, and signaling of B cells. Bruton’s Tyrosine Kinase has been found to regulate cell proliferation, survival, and migration in various B-cell malignancies. Targeting BTK with recently developed Bruton’s Tyrosine Kinase inhibitors has been approved by the Food and Drug Administration (FDA) for the treatment of several hematological malignancies and has transformed the treatment of several B-cell malignancies. The roles that Bruton’s Tyrosine Kinase plays in B cells have been appreciated for some time. Recent studies have established that Bruton’s Tyrosine Kinase is expressed and plays pro-tumorigenic roles in several epithelial cancers. In this review, we focus on novel isoforms of the Bruton’s Tyrosine Kinase protein expressed in epithelial cancers. We review recent work on the expression, function, and signaling of these isoforms and their value as potential therapeutic targets in epithelial tumors.
Bruton’s Tyrosine Kinase Epidemiology Insights
According to Cerhan and Habermann (2021), the incidence rate for Marginal Zone Lymphoma (MZL) was 19.6 per 1,000,000 person-years; 9% of MZL cases were splenic MZL (SMZL), 30% nodal MZL (NMZL), and 61% extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT).
As Per NORD, mantle cell lymphoma (MCL) is an uncommon form of non-Hodgkin’s lymphoma (NHL), accounting for 5–7% of all cases of NHL; about 1 out of 200,000 people worldwide is diagnosed each year with MCL. The disease primarily affects older adults, with males representing approximately three-quarters of those with MCL. Many affected individuals are diagnosed at about 60–70 years old. Reports suggest that most individuals with MCL have advanced (i.e., stage III or stage IV) disease at diagnosis.
Bruton’s Tyrosine Kinase Hematological Cancer epidemiology is segmented as Total Cases of Hematological Cancer, Treatable cases by line of therapies, and Patients on Bruton’s Tyrosine Kinase Hematological Cancer] in the Bruton’s Tyrosine Kinase Hematological Cancer market report.
The Report Covers the Bruton’s Tyrosine Kinase Epidemiology Segmented by –
Bruton’s Tyrosine Kinase prevalent cases
Bruton’s Tyrosine Kinase incident cases
Bruton’s Tyrosine Kinase diagnosed cases
Bruton’s Tyrosine Kinase treatment cases
Click here to learn more about the Bruton’s Tyrosine Kinase Market Landscape
Bruton’s Tyrosine Kinase Market Outlook
Hematological cancer is an area that experts are still studying, and many potential drug candidates are being analyzed for their therapeutic effects. In the coming years, with the emergence of new drugs, the market for the treatment of hematological cancer is expected to witness positive changes. Bruton’s Tyrosine Kinase inhibitors are increasingly used in MCL as chronic suppressive therapy, especially in the elderly. Bruton’s Tyrosine Kinase inhibitors were the most preferred agents in second or later lines of therapy (57%).
The dynamics of Bruton’s Tyrosine Kinase Hematological Cancer market is anticipated to change in the coming years owing to improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the launch of emerging therapies. Key players such as Loxooncology, BeiGene, Nurix Therapeutic, and others are involved in developing therapies for Bruton’s Tyrosine Kinase Hematological Cancer.
According to DelveInsight, Bruton’s Tyrosine Kinase Hematological Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Bruton’s Tyrosine Kinase Market include:
AstraZeneca
Avila Therapeutics
Johnson and Johnson
Ono Pharmaceuticals
And many others
Bruton’s Tyrosine Kinase Therapies Covered in the Report:
Acalabrutinib (ACP-196)
AVL-292
Imbruvica
Tyrosine Kinase Inhibitors
Learn more about Key Companies and Emerging Therapies in the Bruton’s Tyrosine Kinase Market
Table of Contents
Key Insights
Report Introduction
Executive Summary of Bruton’s Tyrosine Kinase Market
Bruton’s Tyrosine Kinase Background and Overview
Bruton’s Tyrosine Kinase Epidemiology and patient population
Bruton’s Tyrosine Kinase Market Emerging Therapies
Bruton’s Tyrosine Kinase Market Cancer Market Outlook
Market Access and Reimbursement of Therapies
Appendix
Market Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
Learn more about detailed report offerings @ Bruton’s Tyrosine Kinase Market Outlook
Trending Reports by DelveInsight
Adalimumab Biosimilar Market
Arbovirus Infection Market
Artificial Pancreas Device System Market
Dental Equipment Market
Gluten Sensitivity Market
Hypothyroidism Market
Inflammatory Bowel Disease Market
Mayus Kinase Jak Inhibitors Market
Mild Dry Eye Market
Mucopolysaccharidosis Market
Oncolytic Virus Cancer Therapy Market
Pyoderma Gangrenosum Market
Transdermal Drug Delivery Devices Market
Intrathecal Pumps Market
Hedgehog Pathway Inhibitors Market
Yellow Fever Market
Laryngeal Cancer Market
Female Infertility Market
Gender Dysphoria Market
Chronic Brain Damage Market
Spain Healthcare Outlook Market
Malignant Fibrous Histiocytoma Market
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
